Hyaluronidase (human recombinant) is an enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents. Hyaluronidase (human recombinant) (INN Vorhyaluronidase alfa) is produced by genetically engineered Chinese Hamster Ovary (CHO) cells containing a DNA plasmid encoding for a soluble fragment of human hyaluronidase (PH20).
- Mechanism
- Curator reviewed · 5 references
Hyaluronidase cleaves hyaluronic acid at the glucosaminidic bond between C1 of glucosamine and C4 of glucuronic acid. Hyaluronic acid is a key component of the extracellular matrix. Injection of hyaluronidase with other fluids, drugs, or radiopaque agents improves the ability of these other compounds to permeate the extracellular space more easily.
- Primary indication
- Hyaluronidase is indicated for subcutaneous fluid administration for hydration, and increasing resorption of radiopaque agents in subcutaneous urography.Curator reviewed · 75 structured indications
- Formula / weight
- 61000.0 Da
- First approval
- Canada, 2022 · United States, 2005
- Also known as
- Hyaluronidase human recombinant · Hyaluronidase recombinant human · hyaluronidase-fihj · hyaluronidase-oysk · hyaluronidase-qvfc
- Code names
- RHUPH-20
- Brand names
Resolves to
What you can answer from here — as of January 08, 2026
Which drugs share a target with Hyaluronidase (human recombinant), and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account